🔎 Trials Near Me

Acasă › Neuroblastom › District of Columbia

Studii clinice pentru Neuroblastom în District of Columbia

6 studii pentru Neuroblastom caută participanți în District of Columbia.

Orașe în District of Columbia

Text oficial al studiului (în engleză)

Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma

  • Children's National Medical Center, Washington D.C.
În curs de recrutareFaza 3
Până la vârsta de 30 · Toate sexele · Actualizat 2 oct. 2026 · NCT06172296

Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)

  • Children's National Medical Center, Washington D.C.
În curs de recrutareFaza 3
365 Days – 30 Years · Toate sexele · Actualizat 25 aug. 2026 · NCT03126916

Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

  • Children's National Medical Center, Washington D.C.
În curs de recrutareFaza 1/2
12 Months – 30 Years · Toate sexele · Actualizat 25 aug. 2026 · NCT04851119

Selective Antigen Specific T Cells and CAR T Cells in Subjects With Relapsed/Refractory Embryonal Tumors (SABRE)

  • Children's National Hospital, Washington D.C.
  • Childrens National Hospital, Washington D.C.
În curs de recrutareFaza 1
Vârste de la 1 la 23 · Toate sexele · Actualizat 13 aug. 2026 · NCT07172958

Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma

  • Children's National Medical Center, Washington D.C.
În curs de recrutareFaza 1/2
12 Months – 30 Years · Toate sexele · Actualizat 19 mai 2026 · NCT04901702

A Study of Cabozantinib as a Maintenance Agent to Prevent Progression or Recurrence in High-Risk Pediatric Solid Tumors

  • Children's National Medical Center, Washington D.C.
În curs de recrutareFaza 2
18 Months – 40 Years · Toate sexele · Actualizat 12 aug. 2025 · NCT05135975

Sursă: ClinicalTrials.gov, date preluate la 6 oct. 2026. Fiecare studiu are propriile criterii de eligibilitate; echipa de cercetare decide cine poate participa.